We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Inflammation Key to Severity of Avian Flu

By HospiMedica staff writers
Posted on 22 Nov 2005
The deadly H5N1 strain of avian flu triggers levels of inflammatory proteins that are more than 10 times higher than the common flu virus H1N1. More...
These are likely to result in an uncontrolled inflammatory response that can escalate into life-threatening pneumonia and acute respiratory distress.

To investigate why this strain is so deadly to humans, researchers from the University of Hong Kong and collaborators in Vietnam studied the levels of a subset of the pro-inflammatory proteins, or cytokines and chemokines, induced by the H5N1 virus in human lung cells. They compared these protein levels with levels induced by the human flu virus H1N1.

The results showed that H5N1 is a much more potent inducer of pro-inflammatory proteins than H1N1. One day after infection with H5N1, the levels of the chemokine IP-10 in bronchial epithelial cells reached 2,200 pg/ml, compared to cells infected with H1N1, which reached only 200 pg/ml. The findings were reported in the November 11, 2005, online edition of Respiratory Research (www.biomedcentral.com).

Michael Chan and colleagues from the University of Hong Kong conducted the research. They pointed out that chemokines and cytokines are "messengers of the immune system” and are critical in coordinating and regulating the immune response. Altering this balance is apt to lead to an uncontrolled inflammatory response in the lung, which probably explains in part the severe lung inflammation associated with avian flu virus H5N1.




Related Links:
U. of Hong Kong

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Ureteral Dilatation Balloon
Dornier Equinox
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.